Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Chemmedchem|October 22, 2024
Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9Philipp Grosche, Alec N Flyer, Raphael Gattlen, et al.Vaccine|July 28, 2010
Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderlyTsui Mai Kao, Szu Min Hsieh, Hsiang Chi Kung, et al.Investigational New Drugs|December 15, 2012
Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferonsFrank Leigh Lu, Ching-Chia Yu, Huei-Hsuan Chiu, et al.Plos One|December 31, 2021
Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapyHassan Issafras, Shilong Fan, Chi-Ling Tseng, et al.Frontiers in Immunology|March 6, 2025
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicityFan Ye, Jianing Huang, Xiaoli Cheng, et al.European Journal of Medicinal Chemistry|June 18, 2015
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutationsChiung-Tong Chen, John T-A Hsu, Wen-Hsing Lin, et al.Journal of Medicinal Chemistry|May 27, 2017
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxCGrazia Piizzi, David T Parker, Yunshan Peng, et al.The Lancet. Oncology|June 21, 2013
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialYi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, et al.Journal of Hematology & Oncology|April 18, 2020
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Yongping Song, Yan Qin, et al.Cell Chemical Biology|September 21, 2021
Identification of a PCSK9-LDLR disruptor peptide with in vivo functionMargaret E Brousseau, Kevin B Clairmont, Glen Spraggon, et al.Pageof 6